US Patent

US10201584 — Compositions and methods for treating HCV

Method of Use · Assigned to AbbVie Inc · Expires 2032-05-17 · 6y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical compositions that combine two or more therapeutic agents to inhibit the hepatitis C virus.

USPTO Abstract

This disclosure is directed to pharmaceutical compositions that comprise two or more therapeutic agents that, inter alia, are useful for inhibiting hepatitis C virus (HCV) and methods for inhibiting HCV by co-administering two or more anti-HCV therapeutic agents.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1889`	—

Patent Metadata

Patent number: US10201584
Jurisdiction: US
Classification: Method of Use
Expires: 2032-05-17
Drug substance claim: No
Drug product claim: No
Assignee: AbbVie Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.